TY - JOUR
T1 - Effect of continuous positive airway pressure on blood pressure in obstructive sleep apnea with cardiovascular disease
AU - Van Ryswyk, Emer
AU - Anderson, Craig S.
AU - Barbe, Ferran
AU - Loffler, Kelly A.
AU - Lorenzi-Filho, Geraldo
AU - Luo, Yuanming
AU - Quan, Weiwei
AU - Wang, Jiguang
AU - Zheng, Danni
AU - McEvoy, R. Doug
PY - 2019/1/1
Y1 - 2019/1/1
N2 - To the Editor:
Obstructive sleep apnea (OSA) is consistently associated with increased risk for cardiovascular (CV) disease (1), but the large-scale, international SAVE (Sleep Apnea and Cardiovascular Endpoints) randomized trial showed that continuous positive airway pressure (CPAP) treatment did not prevent serious CV events in high-risk patients (2). One explanation is that SAVE showed a nonsignificant, <1.0 mm Hg systolic blood pressure (BP) difference between CPAP-treated and usual care (UC) groups over a mean follow-up of 3.7 years, which was smaller than expected based on short-term trials (3). To provide greater insight into the SAVE results, we wish to report further data on mean BP and visit-to-visit BP variability (BPV) across the first 24 months of the study. Although increasing evidence supports an association of BPV and CV events (4), the importance of this key BP parameter in relation to CPAP treatment for OSA is uncertain (5, 6). Some of these results have been presented in abstract form (7, 8).
AB - To the Editor:
Obstructive sleep apnea (OSA) is consistently associated with increased risk for cardiovascular (CV) disease (1), but the large-scale, international SAVE (Sleep Apnea and Cardiovascular Endpoints) randomized trial showed that continuous positive airway pressure (CPAP) treatment did not prevent serious CV events in high-risk patients (2). One explanation is that SAVE showed a nonsignificant, <1.0 mm Hg systolic blood pressure (BP) difference between CPAP-treated and usual care (UC) groups over a mean follow-up of 3.7 years, which was smaller than expected based on short-term trials (3). To provide greater insight into the SAVE results, we wish to report further data on mean BP and visit-to-visit BP variability (BPV) across the first 24 months of the study. Although increasing evidence supports an association of BPV and CV events (4), the importance of this key BP parameter in relation to CPAP treatment for OSA is uncertain (5, 6). Some of these results have been presented in abstract form (7, 8).
KW - Cardiovascular disease
KW - Sleep apnea
KW - CPAP
KW - blood pressure
UR - http://www.scopus.com/inward/record.url?scp=85066482334&partnerID=8YFLogxK
UR - http://purl.org/au-research/grants/NHMRC/1006501
UR - http://purl.org/au-research/grants/NHMRC/1060078
U2 - 10.1164/rccm.201811-2200LE
DO - 10.1164/rccm.201811-2200LE
M3 - Letter
C2 - 30849229
AN - SCOPUS:85066482334
SN - 1073-449X
VL - 199
SP - 1433
EP - 1435
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 11
ER -